
    
      This study will have two parts: Phase 1b and Phase 2. The part that patients may participate
      in will depend on when they join the study.

      In the phase 1b portion of the study, small groups participants will receive increasing doses
      of venetoclax in combination with a flat dose of enadisenib until the highest dose or best
      dose of venetoclax that is safe and tolerable in combination with enadisenib is found.

      In the phase 2 portion of the study, an additional group of participants will receive the
      highest or best dose of venetoclax found in the Phase 1b portion of the study with a flat
      dose of enadisenib to see how useful the combination is in treating relapsed or refractory
      acute myeloid leukemia (AML).
    
  